Overview
At Oxford Drug Design we leverage our knowledge of tRNA synthetases (aaRS) to rapidly advance multiple drug candidates to the clinic – promising new therapies designed to treat major diseases where this enzyme family plays a key role.
We focus on identifying novel disease targets based on the non-canonical functions of aaRS, and integrate this new biochemistry with our pioneering computational platform trained specifically on this target family.
